The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 09, 2023
Filed:
Nov. 19, 2019
Suzhou Yi-hua Biomedical Technology Co., Ltd, Jiangsu, CN;
Suzhou Ronnsi Pharma Co., Ltd., Jiangsu, CN;
Yongsheng Jin, Jiangsu, CN;
Xiujuan Ding, Jiangsu, CN;
Wu Chen, Jiangsu, CN;
Xiaoming Li, Jiangsu, CN;
Junting Sun, Jiangsu, CN;
Yihao Zhu, Jiangsu, CN;
Xiaohua Lu, Jiangsu, CN;
Caijuan Jin, Jiangsu, CN;
Hua Zhou, Jiangsu, CN;
Ningxia Wang, Jiangsu, CN;
Yongbao Li, Jiangsu, CN;
Qiaoyun Zhou, Jiangsu, CN;
Jiangen Qian, Jiangsu, CN;
Xi Chong, Jiangsu, CN;
Yiming Yao, Jiangsu, CN;
Yi Jiang, Jiangsu, CN;
Other;
Abstract
Provided is a low-molecular-weight holothurian glycosarninoglycan, with the constituent units thereof being a glucuronic acid group, an N-acetaminogalactose group and a fucose group, and a sulfate ester group or acetyl ester group thereof. Glucuronic acid and N-acetaminogalactose are interconnected via β(1-3) and β(1-4) glucosidic bonds to form a backbone of a disaccharide repeating structural unit, and a fucose group is connected to the backbone as a side chain. On a molar ratio basis, the ratio of the glucuronic acid group:the N-acetaminogalactose group:the fucose group is 1:(0.8-1.2):(0.6-1.2). In the structure of the low-molecular-weight holothurian glycosaminoglycan, 10-30% of glucuronic acid groups are modified, on the 2-position, with a sulfate ester group, and the rest are hydroxyl groups; and a proportion of 10-30% of fucose groups is modified, on the 2-position, with an acetyl ester group, and the rest are hydroxyl or sulfate ester groups. The low-molecular-weight holothurian glycosarninoglycan of the present invention has anti-inflammation, anti-vasculopathy, anti-tumor or anti-tumor-metastasis functions, and the effect of improving learning and memory abilities, and can be used for preparing a related drug or health-care product.